Therapeutic use of antithrombin concentrate in sepsis

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 2, 1998, Pages 183-194

  Balk, Robert ^a   Emerson, Thomas ^b   Fourrier, Francois ^c   Kruse, James A ^d   Mammen, Eberhard F ^d,g   Schuster, Hans Peter ^e   Vinazzer, Helmut ^f  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BAYER CORPORATION   (United States)

^c UNIV LILLE   (France)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Diakonissenkrankenhaus   (Germany)

^f Blood Coagulation Laboratory   (Austria)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin; Antithrombin concentrate; Antithrombin supplementation; Disseminated intravascular coagulation (DIC); Multiple organ dysfunction syndrome (MODS); Sepsis

Indexed keywords

ANTITHROMBIN;

ARTICLE; CLINICAL RESEARCH; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG RESEARCH; HUMAN; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPSIS;

EID: 0031894499     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995839     Document Type: Article

References (86)

1. Bone RC, Balk RA, Cerra FB, ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655
2. Bernard GR, Sepsis trials, intersection of investigation, regulation, funding, and practice. Am J Resp Crit Care Med 1995;152:4-10
3. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corlicosteroids in patients with septic shock: A prospective, controlled study. N Engl J Med 1984;311:1137-1143
4. Bernard GR, Harris T, Luce JE, et al. High dose corticosteroids in patients with the adult respiratory distress syndrome: A randomized double-blind trial. N Engl J Med 1987;317:1565-1570
5. Department of Health and Human Services, Centers for Disease Control. Increase in national hospital discharge survey ratios for septicemia: United States 1979-1987. MMWR 1990;39: 31-34
6. Bone RC, Fisher CJ Jr, Clemmar TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: Valid clinical entity. Crit Care Med 1989;17:389-393
7. Glauser MP, Zunetti G, Baumgartner JD, Cohen J. Septic shock: Pathogenesis. Lancet 1991;338:732-736
8. Hack CE, Thijs LG. The orchestra of mediators in the pathogenesis of septic shock: A review. In: Vincent JL, ed. Update in Intensive Care and Emergency Medicine. Berlin: Springer; 1991: 232-246
9. Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992;152:1381-1389
10. Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-979
11. Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemostas 1996;75: 902-907
12. Hekman CM, Laskutoff DJ. Kndothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1989;260:11581-11587
13. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991;44:139-143
14. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985;75:818-821
15. Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin I induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986;163:1595-1600
16. van Hinsbergh VWM, Kooistra T, van den Berg EA, Princen MMG, Fiers W, Emeis JJ. Tumor necrosis factor increases production of plasminogen activator inhibitor in human endothelial cells in vitro and rats in vivo. Blood 1988;72: 1467-1473
17. Gelehrter TD, Sznycer-Laszuk R: Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986;76:165-169
18. Levi M, van der Poll T, ten Cate H, van Deventer SJH. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 1997;27:3-9
19. Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple organ failure syndrome. Arch Surg 1986;121:196-208
20. Paloma MJ, Paramo JA, Rocha E. Endotoxin-induced intravascular coagulation in rabbits: Effect of tissue plasminogen activator vs urokinase on PAI generation, fibrin deposits and mortality. Thromb Haemostas 1995;74:1578-1582
21. Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: Relation to outcome. Crit Care Med 1989;17:724-733
22. Pralong G, Calandra T, Glauser M-P, et al. Plasminogen activator inhibitor 1: A new prognostic marker in septic shock. Thromb Haemostas 1989;61:459-462
23. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990;57:271-278
24. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemostas 1996; 75:224-228
25. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973;248:6490-6506
26. Mummen EF, Clinical relevance of antithrombin deficiencies. Semin Hematol 1995;32(Suppl 2):2-6
27. Mammen EF, Miyakawa T, Phillips TF, Assarian GS, Brown JM, Murano G. Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin Thromb Hemostas 1985;11:373-383
28. Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E. Studies of components of the coagulation system in normal individuals and septic shock patients. Circ Shock 1982;9:491-497
29. 1-inhibitor and α2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 1984;82:396-404
30. Wilson RF, Mammen EF, Robson MC, Heggers JP, Soullier G, De Poli PA. Antithrombin, prekallikrein and fibronectin levels in surgical patients. Arch Surg 1986;121:635-640
31. Wilson RF, Farag AM, Mammen EF, Fujii Y. Sepsis and antithrombin III, prekallikrein and fibronectin levels in surgical patients. Am Surgeon 1989;55:450-456
32. Wilson RF, Mammen EF, Tyburski JG, Warsow KM, Kubinec SM. Antithrombin levels related to infections and outcome. J Trauma 1996;40:384-387
33. Hellgren M, Egberg N, Eklund J. Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intensive Care Med 1984;10:23-29
34. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
35. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VII and antithrombin III activity during sepsis and septic shock in neutropenic patients. Blood 1996;88: 881-886
36. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-132
37. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-121
38. Van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-1629
39. Mammen EF. Diagnosis of Disseminated Intravascular Coagulation and Related Consumptive Coagulopathies. Patterson, NJ: Cadeceus Medical Publishers; 1992:3-14
40. Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombohemorrhagic disorders. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 3rd ed. Philadelphia, PA: Lippincott: 1994:1023-1063
41. Bauer KA, Weitz JI. Laboratory markers of coagulation and fibrinolysis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 3rd ed. Philadelphia, PA: Lippincott; 1994:1197-1210
42. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988;59: 101-106
43. Lau HK, Rosenberg JS, Beeler DL, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and F 1+2. J Biol Chem 1979;254:8751-8762
44. Nossel H, Younger L, Wilner G, Procupez T, Canfield R, Butler V Jr. Radioimmunoassay of human fibrinopeptide A. Proc Natl Acad Sci USA 1971;68:2350-2359
45. Marder VJ, Matchett MO, Sherry S. Detection of serum fibrinogen and fibrin degradation products. Am J Med 1971;51:71-78
46. Rylatt DB, Blake AS, Cottis LE, et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31:767-778
47. Collen D, de Cock F, Cambiaso CL, Masson P. A latex agglutination test for rapid quantitative estimation of the plasmin-antiplasmin complex in human plasma. Eur J Clin Invest 1977;7:21-32
48. van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxin in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2528
49. Harper PL, Park GR, Carrell RW. The plasma turnover of transfused antithrombin concentrate in patients with acquired anti-thrombin deficiency. Transf Med 1996;6:45-50
50. Jourdain M, Fourrier F, Tournoys A, Mangalaboyi J, Goudemond J, Chopin C. Effects of a combined regimen of antithrombin III and protein C substitution in porcine acute endotoxic shock. Proc Eur Intens Care Med 1997;119 (Abst)
51. Kruse JA, Mammen EF. Plasma antithrombin III activity in patients with sepsis. Crit Care Med 1996;23(Suppl):A97(Abst)
52. Schuster HP, Matthias FR. Antithrombin III in patients with severe sepsis. 15th Int Symp Intensive Care and Emergency Med, Brussels, Belgium. 1995;92-98
53. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial. In press
54. Esmon PC, Yee E. Enzyme-linked immunosorbent assay for proteolytically inactivated antithrombin III: Use of sodium dodecyl sulfate to eliminate signal due to intact antithrombin III. Anal Biochem 1992;202:344-347
55. Pritchard JA, Brekken AL. Clinical and laboratory studies on severe abruptio placentae. Am J Obstet Gynecol 1967;97:681-694
56. Karges HE, Heimburger N. Grundlagen und Biochemie des Antithrombin III. In: Köstering H. Amithrombin III. Grundlagen, Diagnostik, Klinische Bedeutung und Therapie. Stuttgart: Schattauer; 1984:7-16
57. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;29.1404-1411
58. Horie S, Ischii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904
59. Okajima K. New therapeutic implications of antithrombin III replacement in disseminated intravascular coagulation and multiple organ failure. Intensivmedizin 1996;33:5-11
60. Krausz MM, Utsunomiya T, Fenerstein G, Walfa JHN, Shepro D, Hechtman HB. Prostacyclin reversal of lethal endotoxemia in dogs. J Clin Invest 1981;67:1118-1125
61. Eisenhut T, Sinha B, Gottrup-Wolfers E, Semmler J, Siess W, Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993;26:259-264
62. Jochum M, Inthorn D, Machleidt W, Waydhas CH, Fritz H. Influence of proteinase inhibitor therapy on the release of cellular proteinases, cytokines and soluble adhesion molecules in acute inflammation. Circ Shock Suppl 1993;1:41 (Abst)
63. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995;32(Suppl 2):19-32
64. Obertacke U, Kleinschmidt C, Jochum M, et al. Reduction of shock-related complications and pulmonary microvascular permeability by continuous application of antithrombin III (140% serum activity) for 4 days after trauma - preliminary results of a prospective clinical study. Circ Shock 1993; (Suppl 1):41 (Abst)
65. Ushiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996;270:L921-L930
66. Frebelius S, Hedin U, Swedenborg J. Thrombogenicity of the injured vessel wall - role of antithrombin and heparin. Thromb Haemostas 1994;71:147-153
67. Emerson TE Jr. Antithrombin III replaeement in animal models of acquired antithrombin III deficiency. Blood Coag Fibrinolysis 1994;5(Suppl 1):S37-S45
68. Prager RL, Dunn EL, Kirsh MM, Penner JA. Endotoxin-induced intravascular coagulation (DIC) and its therapy. Adv Shock Res 1979;2:277-287
69. Jordan RE, Kilpatrick J, Nelson RM. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 1987; 237:777-779
70. Lollar P, Macintosh SC, Owen WG. Reaction of AT-III with thrombin bound to vascular endothelium. J Biol Chem 1984; 259:4335-4338
71. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981;78:2249-2252
72. Kamikubo Y, Hamuro T, Matsuda J, et al. Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: Concerted effect with antithrombin. Thromb Haemostas 1996;76:621-626
73. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985;39:81-89
74. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemostas 1989;15:347-352
75. Fourrier F, Chopin C, Huart J, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-888
76. Lamy M, Eisele B. Keinecke H-O, Delvos U, Thijs LG. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial. In: Bennett D. ed. 9th European Congress on Intensive Care Medicine, Glasgow, Scotland, 1996;385-390
77. Balk R, Bedrosian C, McCormick L, et al. Prospective, double-blind. placebo-controlled, trial of AT III substitution in sepsis, 8th European Congress of Intensive Care Medicine, Athens, Greece 1995:7-11 (from bound abstracts)
78. Diaz-Cremades JM, Lorenzo R, Sanehez M, et al. Use of antithrombin III in critical patients. Intensive Care Med 1994; 20:577-580
79. Guidici D, Gallioli G, Wolfler A, et al. AT III in the ICU patient: a randomized double blind trial. In: Braschi A, Chiaranda M, Gattinoni L, Pesenti A, Raimondi F. Simposio Mostra Anestesia Rianimazione e Terapia Intensiva. Berlin: Springer; 1997: 9-12
80. Van Beek EJR, von der Möhlen MAM, ten Cate JW, Brandjis BPM, Büller HR. Antithrombin III concentrate in the treatment of DIC: A retrospective follow-up study. Netherlands J Med 1994;45:206-210
81. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-918
82. Taylor FB Jr. Emerson TE Jr, Jordan R, Chang AK, Blick KE. Antithrombin III prevents lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-235
83. Kessler CM, Tang ZCH, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate in Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity. Blood 1997;89:4393-4401
84. Seitz R, Wolf M, Egbring R, Radtke KP, Liesenfeld A, Pittner P. Participation and interaction of neutrophil elastase in haemostatic disorders in patients with severe infections. Eur J Haematol 1987;38:231-240
85. Jordan RE, Nelson MR, Kilpatrick J, Newgren JO, Esmon PC. Fournel MA. Inactivation of human antithrombin by neutrophil elastase. J Biol Chem 1989;264:10493-10500
86. Jordan RE, Kilpatrick J, Nelson RM. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 1987; 237:777-779